[
  {
    "ts": null,
    "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
    "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
    "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752622845,
      "headline": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns",
      "id": 135959071,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1401241138/image_1401241138.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock a strong long-term opportunity.",
      "url": "https://finnhub.io/api/news?id=dd95196df08df83dcb835a89e877361f36e0ec6beb9048b6078e84cf1c31a0ac"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors",
    "summary": "Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=8058a821605d6d2f6ba696ac4825343a8f897237b763186bb44cb57eb75743d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752616805,
      "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors",
      "id": 135965574,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=8058a821605d6d2f6ba696ac4825343a8f897237b763186bb44cb57eb75743d5"
    }
  },
  {
    "ts": null,
    "headline": "Exploring 3 High Growth Tech Stocks In The US Market",
    "summary": "As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by companies like Nvidia. In this dynamic environment, identifying high-growth tech stocks involves looking at those that can leverage current trends such as AI advancements and strategic partnerships to sustain their momentum in a competitive landscape.",
    "url": "https://finnhub.io/api/news?id=2fd285715b0f0c07b7b332892025a355466976986460530cd58e67451ebf62aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752601517,
      "headline": "Exploring 3 High Growth Tech Stocks In The US Market",
      "id": 135957309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "As the U.S. stock market experiences mixed movements with major indexes reaching record highs amidst inflation data and earnings reports, the tech sector stands out with notable rallies spurred by companies like Nvidia. In this dynamic environment, identifying high-growth tech stocks involves looking at those that can leverage current trends such as AI advancements and strategic partnerships to sustain their momentum in a competitive landscape.",
      "url": "https://finnhub.io/api/news?id=2fd285715b0f0c07b7b332892025a355466976986460530cd58e67451ebf62aa"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment",
    "summary": "Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement agreement for the cystic fibrosis treatment ALYFTREK underscores VRTX's therapeutic expansion and patient outreach, counteracting any potential negative market effects from removing the stock from various value indices like the Russell 1000. Positive news on other fronts like long-term data for...",
    "url": "https://finnhub.io/api/news?id=dc81b10e808149a81c932a47acbe08a8ce25b03dc04ebfc7fd44007f6a6cd311",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752600602,
      "headline": "Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment",
      "id": 135965576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement agreement for the cystic fibrosis treatment ALYFTREK underscores VRTX's therapeutic expansion and patient outreach, counteracting any potential negative market effects from removing the stock from various value indices like the Russell 1000. Positive news on other fronts like long-term data for...",
      "url": "https://finnhub.io/api/news?id=dc81b10e808149a81c932a47acbe08a8ce25b03dc04ebfc7fd44007f6a6cd311"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=78e6190beba51c50ac5c739c6f0e129226c3d9d6183ebbc619e8b63534cbeeb3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752597480,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "id": 135977876,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=78e6190beba51c50ac5c739c6f0e129226c3d9d6183ebbc619e8b63534cbeeb3"
    }
  },
  {
    "ts": null,
    "headline": "EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis. The approval comes on the basis of ALYFTREK demonstrating non-inferiority compared to the existing treatment, KAFTRIO, in terms of lung function measurement. “Deutivacaftor/tezacaftor/vanzacaftor […]",
    "url": "https://finnhub.io/api/news?id=c0017a2d3f0e6e60212f69ad0c99f9d0bc4682d974af25e00e750ad11f9cabc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752585042,
      "headline": "EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment",
      "id": 135965578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the European Commission approved the company’s new cystic fibrosis treatment, ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) for treating cystic fibrosis. The approval comes on the basis of ALYFTREK demonstrating non-inferiority compared to the existing treatment, KAFTRIO, in terms of lung function measurement. “Deutivacaftor/tezacaftor/vanzacaftor […]",
      "url": "https://finnhub.io/api/news?id=c0017a2d3f0e6e60212f69ad0c99f9d0bc4682d974af25e00e750ad11f9cabc9"
    }
  },
  {
    "ts": null,
    "headline": "Vertex and NHS England agree reimbursement for Alyftrek",
    "summary": "Alyftrek is approved for individuals aged six years and older with at least one F508del mutation.",
    "url": "https://finnhub.io/api/news?id=488d1f7ba77e721c06643d5152da28f6816da9ba00c216b62a2e8b1ea3c04f05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752580694,
      "headline": "Vertex and NHS England agree reimbursement for Alyftrek",
      "id": 135942767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Alyftrek is approved for individuals aged six years and older with at least one F508del mutation.",
      "url": "https://finnhub.io/api/news?id=488d1f7ba77e721c06643d5152da28f6816da9ba00c216b62a2e8b1ea3c04f05"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value",
    "summary": "Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their estimated value can provide investors with potential opportunities for growth and stability.",
    "url": "https://finnhub.io/api/news?id=89866a5794178f5abe6c733e076e03f4cb7f5dcfd22941df74195f55268d9b3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752579478,
      "headline": "Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value",
      "id": 135942498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Over the last 7 days, the United States market has remained flat, yet it has experienced an 11% increase over the past year with earnings projected to grow by 15% annually. In this environment, identifying stocks that may be trading below their estimated value can provide investors with potential opportunities for growth and stability.",
      "url": "https://finnhub.io/api/news?id=89866a5794178f5abe6c733e076e03f4cb7f5dcfd22941df74195f55268d9b3c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug",
    "summary": "NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.",
    "url": "https://finnhub.io/api/news?id=8809e6d43911ea054913596756bcfd273f9d813e2cf8e07dda612f2c71083d7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752575460,
      "headline": "Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug",
      "id": 135957803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.",
      "url": "https://finnhub.io/api/news?id=8809e6d43911ea054913596756bcfd273f9d813e2cf8e07dda612f2c71083d7e"
    }
  },
  {
    "ts": null,
    "headline": "Harding Loevner Global Equity Q2 2025 Report",
    "summary": "The Global Equity composite rose 10.3% gross of fees in the second quarter, lagging the 11.7% gain in the MSCI ACWI Index.",
    "url": "https://finnhub.io/api/news?id=8ec65fb5791a8926881b2ee37698c3f7289d7fd8997db8809c0e93fef327274b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752573600,
      "headline": "Harding Loevner Global Equity Q2 2025 Report",
      "id": 135945766,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2067714497/image_2067714497.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The Global Equity composite rose 10.3% gross of fees in the second quarter, lagging the 11.7% gain in the MSCI ACWI Index.",
      "url": "https://finnhub.io/api/news?id=8ec65fb5791a8926881b2ee37698c3f7289d7fd8997db8809c0e93fef327274b"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Growth Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Growth Equity Fund (Investor Shares) returned 18.97% (net of fees) during the quarter, outperforming the Russell 1000 Growth Indexâs 17.84%. Read more here.",
    "url": "https://finnhub.io/api/news?id=76cb4babf97141731cff29a2d4e1fa66167489bdd2866cdffbd4540e8483e33e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752567720,
      "headline": "Parnassus Growth Equity Fund Q2 2025 Commentary",
      "id": 135943109,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182036952/image_2182036952.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Parnassus Growth Equity Fund (Investor Shares) returned 18.97% (net of fees) during the quarter, outperforming the Russell 1000 Growth Indexâs 17.84%. Read more here.",
      "url": "https://finnhub.io/api/news?id=76cb4babf97141731cff29a2d4e1fa66167489bdd2866cdffbd4540e8483e33e"
    }
  },
  {
    "ts": null,
    "headline": "Parnassus Core Equity Fund Q2 2025 Commentary",
    "summary": "Parnassus Core Equity Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=7f21b46d510fc34a6ca2316565655fc51487440827c8a003d40c5ac7d653cd0c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752566520,
      "headline": "Parnassus Core Equity Fund Q2 2025 Commentary",
      "id": 135942651,
      "image": "",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7f21b46d510fc34a6ca2316565655fc51487440827c8a003d40c5ac7d653cd0c"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated Announces Broad Reimbursement Agreement with NHS England for ALYFTREK®? an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "Vertex Pharmaceuticals Incorporated announced that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis medicine ALYFTREK®? . This agreement comes as the...",
    "url": "https://finnhub.io/api/news?id=c894b8067b84e5173054f62b20978e42a79415cb53784f3e1b4d3e3ad16948c9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752545126,
      "headline": "Vertex Pharmaceuticals Incorporated Announces Broad Reimbursement Agreement with NHS England for ALYFTREK®? an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 135934722,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "Vertex Pharmaceuticals Incorporated announced that it has reached a broad reimbursement agreement with NHS England for Vertex's cystic fibrosis medicine ALYFTREK®? . This agreement comes as the...",
      "url": "https://finnhub.io/api/news?id=c894b8067b84e5173054f62b20978e42a79415cb53784f3e1b4d3e3ad16948c9"
    }
  }
]